Web Exclusives

NORM is here to partner with you to chart a course of continued success and sustainability. Change is never easy, but in the rheumatology world, it is a constant. Preparing our physicians and staff to anticipate changes and effectively navigate them is part of our job as leaders within our practices.

• Subcutaneous Tocilizumab Approved for Polyarticular Juvenile Idiopathic Arthritis
• Baricitinib Receives Approval for Treatment of Moderate-to-Severe RA

According to the results of 2 separate clinical trials presented at the 2018 Genitourinary Cancers Symposium, apalutamide and enzalutamide reduced the risk for metastasis and prolonged metastasis-free survival in patients with nonmetastatic castrate-resistant prostate cancer.

Our news blog is comprised of several categories, including Healthy Lifestyle, Holidays, Industry News, Minute with the Board, NORM Events, NORM News, Resources, Social Media, and Tips and Tricks.

• Ixekizumab Approved for Adults with Psoriatic Arthritis
• Biosimilar to Infliximab Approved for All Eligible Indications of Reference Drug
• Tofacitinib and Tofacitinib Extended Release Approved for Adults with Psoriatic Arthritis

Happy holidays and warmest wishes to you and your staff from the National Organization of Rheumatology Managers (NORM)!

In a recent interview, Ms Zlatkus shared comments about her aspirations as President of NORM and Editor-in-Chief of RPM.

Scott Gottlieb was recently confirmed as FDA Commissioner. It is believed that he would be able to swiftly execute changes that could help to accelerate drug approvals and lower drug prices to meet Trump’s goals.